Although rare, an allergy to these medications is also possible
Start your intake State-by-State Medicaid GLP-1 Coverage: What You Need to Know As of 2024, approximately 30 state Medicaid programs cover GLP-1 medications for weight loss, though many limit coverage to patients with BMI 30 kg/m plus at least one obesity-related comorbidity (hypertension, type 2 diabetes, sleep apnea, or cardiovascular disease)
Emerging research suggests these drugs can lower systemic inflammation and improve insulin resistance in conditions like PCOS (polycystic ovary syndrome) even at lower doses
In addition to glycemic changes, a substantial reduction in body weight was also observed
demonstrated that pharmacological activation of GLP-1 signaling ameliorated cystogenesis and renal dysfunction in a zebrafish model of nephronophthisis, a ciliopathy characterized by progressive kidney failure [66]
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
